Trestolone (MENT)
A research compound investigated for male contraception that never received FDA approval.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
Trestolone (MENT)
A research compound investigated for male contraception that never received FDA approval.
Evidence category: Preclinical. This describes the source category, not approval or certainty.
Regulatory statement in source: Never received FDA approval; its IND application lapsed in 2010.
Trestolone (7α-methyl-19-nortestosterone, MENT) was first synthesized in 1963 and investigated by the Population Council as a candidate for male hormonal contraception and hypogonadism treatment. Despite promising results in the 1990s, it failed to receive FDA approval. No IND application renewal since 2010; Schedule III controlled substance.
Benefits reported in the imported source
- Research suggested potential for male contraception and hypogonadism treatment
Risks and limits
- No FDA approval; IND application not renewed since 2010
- Uncertain long-term prostate and cancer safety
- Schedule III controlled substance
- Absence of long-term human safety data
Source bottom line: Preclinical and early-stage research only; never received FDA approval despite promising initial results.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
No study protocol recorded in this snapshot. This does not establish that no study exists.
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — Trestolone (MENT) Compound Profile - Biomogging
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: Users on Biomogging report trestolone acetate dosing of 25-30 mg daily for entry level, 35-50 mg daily for most users, and 60-75 mg daily for advanced users administered via daily subcutaneous injection.
Unverified imported account — Trestolone Administration and Dosing - Biomogging
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A protocol shared on Biomogging describes splitting doses above 40 mg daily into AM and PM administrations, with 6-10 week cycles typical, often stacked with 150-200 mg weekly testosterone base.
Pharmacokinetic context
No half-life recorded in this source snapshot. No value has been inferred.
Source references
- Investigations Into Human Metabolism of Trestolone - PubMed Central (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
- Trestolone - Wikipedia
Snapshot provenance
Source ID: catalog:hormone:trestolone. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.